PPLPHARMA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.7
| Stock Code | PPLPHARMA | Market Cap | 21,322 Cr. | Current Price | 160 ₹ | High / Low | 221 ₹ |
| Stock P/E | 27.6 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.1 % |
| ROE | 10.4 % | Face Value | 10.0 ₹ | DMA 50 | 165 ₹ | DMA 200 | 172 ₹ |
| Chg in FII Hold | 0.51 % | Chg in DII Hold | -0.07 % | PAT Qtr | 313 Cr. | PAT Prev Qtr | 151 Cr. |
| RSI | 40.7 | MACD | -1.50 | Volume | 38,75,596 | Avg Vol 1Wk | 36,27,654 |
| Low price | 132 ₹ | High price | 221 ₹ | PEG Ratio | 0.23 | Debt to equity | 0.12 |
| 52w Index | 31.5 % | Qtr Profit Var | 13.0 % | EPS | 5.27 ₹ | Industry PE | 32.1 |
Analysis: PPLPHARMA shows fair swing trade potential with improving fundamentals but weak technicals. The RSI at 40.7 indicates oversold conditions, while MACD at -1.50 reflects bearish sentiment. Current price (160 ₹) is below both 50 DMA (165 ₹) and 200 DMA (172 ₹), showing short-term weakness. Valuation is attractive with a P/E of 27.6 compared to industry average of 32.1, and PEG ratio at 0.23 suggests undervaluation relative to growth. Fundamentals are modest with ROCE at 12.1% and ROE at 10.4%. PAT doubled sequentially (₹151 Cr → ₹313 Cr), showing strong operational improvement. EPS at ₹5.27 provides earnings support.
Optimal Entry Price: Around 155–160 ₹, near support levels.
Exit Strategy: If already holding, consider profit booking near 175–180 ₹ resistance, or trail stop-loss below 150 ₹.
✅ Positive
- 📈 PAT growth from ₹151 Cr. to ₹313 Cr. sequentially.
- 📊 EPS of ₹5.27 and book value of ₹58.2 provide balance sheet strength.
- 💰 Dividend yield of 0.09%, though small, adds stability.
- 📉 Debt-to-equity ratio at 0.12, indicating low leverage risk.
⚠️ Limitation
- ⚠️ ROCE (12.1%) and ROE (10.4%) are modest compared to stronger peers.
- 📉 Stock trading below 200 DMA, showing weak long-term momentum.
- 📊 Dividend yield negligible, limiting income appeal.
📉 Company Negative News
- 📉 DII holding decreased (-0.07%), showing weaker domestic support.
- ⚠️ Quarterly profit variation at +13% is modest compared to sector peers.
📈 Company Positive News
- 📈 FII holding increased (+0.51%), showing foreign investor confidence.
- 📊 PAT doubled quarter-on-quarter, reflecting strong operational improvement.
🏭 Industry
- 🏭 Industry P/E at 32.1, slightly higher than PPLPHARMA’s 27.6, suggesting mild undervaluation.
- 📊 Pharma sector remains resilient, supported by demand for healthcare and generics.
🔎 Conclusion
⚖️ PPLPHARMA is a fair candidate for swing trading with decent fundamentals and improving earnings. Entry near 155–160 ₹ offers a favorable setup, while exit should be considered around 175–180 ₹. Weak technicals limit immediate upside, but growth potential and foreign investor confidence provide stability for short-term trades.
Would you like me to also highlight PPLPHARMA swing trade chart for clearer visualization of entry and exit levels?